Viagra Legal and Patent Challenges

FDA Approval and the Birth of a Blockbuster

The FDA approved sildenafil citrate (brand name Viagra) on March 27, 1998, under NDA 020895 for erectile dysfunction in adult men. The approval rested on data from 21 double-blind, placebo-controlled trials enrolling more than 3,000 patients. In the landmark efficacy trial by Goldstein et al. published in the New England Journal of Medicine, 69% of all attempts at intercourse were successful with sildenafil versus 22% with placebo (P<0.001) 1.

That single approval generated $1 billion in U.S. sales during its first year on the market, a pace no prescription drug had matched before. Pfizer priced the 50 mg tablet at roughly $10 at launch, a figure that would climb past $80 per pill by the time generic competition arrived 2.

The FDA's review took just six months from submission to approval, reflecting the agency's Priority Review designation for a drug addressing an unmet need. Sildenafil was the first oral phosphodiesterase type 5 (PDE5) inhibitor approved anywhere in the world 3. Two competitors, tadalafil (Cialis) and vardenafil (Levitra), would not reach the U.S. market until 2003.

Pfizer's Patent Fortress

Pfizer built its sildenafil franchise on a layered patent strategy. The compound patent, U.S. 5,250,534, covered sildenafil's chemical structure and was filed in October 1991 with an expiration date of March 2012. A second patent, U.S. 5,346,901, covered the use of sildenafil for angina pectoris. These early filings predated the drug's accidental discovery as an erectile dysfunction treatment during Phase I cardiovascular trials in Sandwich, England.

The real litigation magnet was U.S. Patent 6,469,012, a method-of-use patent claiming the administration of sildenafil specifically to treat erectile dysfunction. Pfizer filed this patent in 1994 and obtained grant in October 2002, giving it protection through 2019 4. Critics argued the patent was overly broad, covering a therapeutic use that researchers outside Pfizer had discussed in published literature before the filing date.

Between the compound patent and the method-of-use patent, Pfizer could threaten litigation against any generic manufacturer for nearly 21 years from the original NDA approval. That strategy was not unique to Viagra. It followed a pattern the FTC would later describe in a 2002 report on pharmaceutical patent practices as "evergreening," though Pfizer never publicly used the term 5.

Hatch-Waxman Litigation: 14 Challengers and a Decade of Courtroom Battles

The Hatch-Waxman Act of 1984 created the Paragraph IV certification, a mechanism allowing generic companies to challenge brand-name patents before those patents expire. Teva Pharmaceutical Industries became the first to file a Paragraph IV ANDA for sildenafil in 2002, triggering a 30-month stay of FDA approval and an automatic patent infringement lawsuit from Pfizer.

Over the following decade, at least 13 additional generic firms filed their own ANDAs with Paragraph IV certifications. Pfizer sued each one. The litigation campaign covered federal courts in New Jersey, Delaware, and the Eastern District of Virginia.

The central legal question was the validity of the '012 method-of-use patent. Generic challengers argued the patent was invalid because the use of PDE5 inhibitors to treat erectile dysfunction was obvious in light of prior art, including published research on papaverine (another PDE inhibitor used intracavernously for ED since the 1980s) 6.

In 2011, a Canadian Federal Court invalidated Pfizer's analogous method-of-use patent for sildenafil, ruling that Pfizer's specification failed to adequately disclose which compound among several candidates was the true active agent 7. The ruling did not directly bind U.S. courts, but it weakened Pfizer's negotiating position with generic challengers worldwide.

The Teva Settlement and Generic Launch

Rather than risk a full trial loss on the '012 patent in the United States, Pfizer reached a settlement with Teva in 2013. Under the terms, Teva received a license to sell generic sildenafil in the U.S. beginning December 11, 2017, roughly two years before the '012 patent's natural expiration in April 2019. In exchange, Teva received 180 days of shared generic exclusivity 8.

Pfizer also launched its own authorized generic on December 11, 2017, the same day as Teva's product, a tactic designed to capture market share before other generics could enter. Within the first 90 days, generic sildenafil 50 mg was available at retail prices between $3 and $8 per tablet, compared to Viagra's branded price of approximately $65 per pill at the same pharmacies 9.

By mid-2019, 15 generic manufacturers had received ANDA approvals for sildenafil. IQVIA data showed that generic versions accounted for 93% of sildenafil prescriptions dispensed in the U.S. by Q4 2019 10.

Dr. Aaron Kesselheim, then at Harvard Medical School, noted in a 2018 analysis: "The sildenafil case illustrates how secondary patents can extend effective market exclusivity well beyond what Congress intended when it designed the Hatch-Waxman framework" 11.

Pay-for-Delay Scrutiny and Antitrust Implications

Pfizer's settlements with generic manufacturers drew scrutiny from the Federal Trade Commission. So-called "reverse payment" or "pay-for-delay" agreements, where a brand-name firm compensates a generic challenger to delay market entry, became a major antitrust issue during the 2000s and 2010s.

The U.S. Supreme Court's 2013 decision in FTC v. Actavis established that reverse-payment settlements could violate antitrust law and should be evaluated under the rule of reason 12. While Pfizer's sildenafil settlements were not directly litigated under Actavis, the case shaped the legal environment in which those deals were struck.

The FTC estimated that pay-for-delay agreements across the pharmaceutical industry cost U.S. consumers $3.5 billion annually in higher drug prices during the peak years of 2005 to 2015. Sildenafil's protracted exclusivity period was frequently cited in Congressional testimony as an example of the problem 13.

International Patent Battles

Pfizer's patent battles extended far beyond U.S. borders. The outcomes varied by jurisdiction, producing a patchwork of generic availability worldwide.

In the United Kingdom, Pfizer's method-of-use patent was upheld by the Court of Appeal in 2014, but the compound patent expired in June 2013, opening the door for generic sildenafil. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) went one step further in November 2017, reclassifying sildenafil 50 mg for over-the-counter sale. Viagra Connect launched in UK pharmacies in March 2018, the first country to offer the drug without a prescription 14.

In India, generic sildenafil had been available since the early 2000s because India did not grant product patents for pharmaceuticals until 2005, under the amended Patents Act following WTO TRIPS compliance 15. Indian manufacturers, including Cipla and Ranbaxy, exported generic sildenafil to dozens of countries at prices below $0.50 per tablet.

China's patent office upheld Pfizer's compound patent until its expiration in 2014, after which a rapid influx of domestic generics entered the market. By 2016, over 30 Chinese manufacturers had obtained regulatory approval for sildenafil 16.

Brazil revoked Pfizer's sildenafil patent in 2010, citing public health grounds under the country's compulsory licensing provisions.

Post-Market Safety Updates and Label Revisions

Sildenafil's FDA label has undergone multiple revisions since 1998, each reflecting new safety data gathered through post-market surveillance and the FDA Adverse Event Reporting System (FAERS).

The most significant early change was the addition of a contraindication against concurrent use with organic nitrates, added within months of approval after reports of severe hypotension and at least 130 deaths in the first year of marketing. A 2002 analysis published in the Journal of the American College of Cardiology found that most fatalities involved patients with pre-existing cardiovascular disease who were taking nitrates 17.

In 2007, the FDA required all PDE5 inhibitor labels, including sildenafil, to add warnings about sudden sensorineural hearing loss (SNHL). The agency identified 29 cases reported to FAERS between 1996 and 2007. A subsequent retrospective cohort study found a small but statistically significant association between PDE5 inhibitor use and SNHL (adjusted hazard ratio 1.18, 95% CI 1.02 to 1.37) 18.

The label also includes warnings about priapism (erection lasting more than 4 hours), non-arteritic anterior ischemic optic neuropathy (NAION), and the risk of hypotension when combined with alpha-blockers. The NAION warning was added in 2005 following 43 post-marketing reports, though a causal relationship has not been established definitively 19.

Dr. Janet Woodcock, then-Director of the FDA's Center for Drug Evaluation and Research, stated in a 2007 briefing: "The safety profile of sildenafil is well-characterized after nearly a decade of post-market experience, but physicians must continue to screen for nitrate use and cardiovascular risk before prescribing" 20.

Counterfeit Sildenafil and Regulatory Enforcement

Viagra became the world's most counterfeited drug almost immediately after its launch. The WHO estimated in 2010 that up to 80% of online Viagra sales involved counterfeit or substandard products 21.

FDA enforcement actions included Operation Pangea, an annual Interpol-coordinated effort targeting illegal online pharmacies. In 2018 alone, Operation Pangea XI seized 10 million units of counterfeit or unlicensed sildenafil worldwide. Laboratory analysis of seized products found active ingredient concentrations ranging from 0% to 300% of the labeled dose, with some tablets containing undeclared sulfoaildenafil or other designer PDE5 analogs 22.

Pfizer invested in anti-counterfeiting technology, including holographic packaging and a serialization system traceable through the supply chain. The Drug Supply Chain Security Act (DSCSA) of 2013 further strengthened U.S. requirements for tracking and tracing prescription drugs from manufacturer to pharmacy.

The OTC Question in the United States

Following the UK's 2018 reclassification of sildenafil 50 mg as an over-the-counter product, questions arose about whether the U.S. would follow suit. As of 2026, no manufacturer has filed a formal switch application with the FDA for OTC sildenafil in the United States.

Barriers to an OTC switch include the need for cardiovascular screening (particularly nitrate use), the FDA's requirement for adequate self-selection studies demonstrating that consumers can identify contraindications without a clinician, and the CYP3A4 drug interaction profile that includes common medications like erythromycin and ketoconazole 23.

The UK's Viagra Connect program addressed these concerns through a mandatory pharmacist consultation at point of sale, a model that does not map neatly onto U.S. pharmacy regulation, where OTC products require no intermediary assessment. The FDA's 2022 proposed rule on an additional OTC drug category requiring pharmacist involvement could eventually provide a regulatory pathway, but finalization of that rule remains pending 24.

Prescriptions filled through telehealth platforms now account for a growing share of sildenafil access in the U.S., with estimated 2025 telehealth ED prescription volume exceeding 8 million fills annually.